Two novel vanadium complexes, [V(IV)O(bp-O)(HSO4)] (1) and [V(IV)O(bp-OH)Cl2] x CH3OH (2 x CH3OH), where bp-OH is 2-{[bis(pyrid-2-yl)methyl]amine}methylphenol, were prepared and structurally characterised. EPR spectra of methanol solutions of 2 suggest exchange of Cl- for CH3OH and partial conversion to [VO(bp-OH)(CH3OH)3]2+. Speciation studies on the VO2+-bpOH system in a water/dmso mixture (4...

The effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) on myeloid colony formation were investigated by initial and delayed addition of TPA to the cultures. In the human placental condi tioned medium-stimulated cultures, TPA inhibited normal myeloid colony formation without any change in colony morphology when added at the beginning of culture. However, macrophage-like transformation of myel...

BACKGROUND AND PURPOSE We sought to evaluate the effects of administration of microbubbles (MBs) on the beginning, speed, and degree of middle cerebral artery (MCA) recanalization during systemic thrombolysis and continuous 2-MHz pulsed-wave transcranial Doppler (TCD) monitoring. METHODS We evaluated 111 patients with acute stroke attributable to MCA occlusion treated with intravenous tissue ...

The effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) on myeloid colony formation were investigated by initial and delayed addition of TPA to the cultures. In the human placental conditioned medium-stimulated cultures, TPA inhibited normal myeloid colony formation without any change in colony morphology when added at the beginning of culture. However, macrophage-like transformation of myelo...

Coupling tissue-type plasminogen activator (tPA) to carrier red blood cells (RBC) prolongs its intravascular life span and permits its use for thromboprophylaxis. Here, we studied the susceptibility of RBC/tPA to PA inhibitors including plasminogen activator inhibitor-1 (PAI-1) that constrain its activity and may reduce the duration of its effect. Despite lesser spatial and diffusional limitati...

We synthesized terephthalic acid (TPA) from p-xylene at an initial concentration above its solubility limit in high-temperature liquid water (HTW). The nominal p-xylene loading at the reaction conditions was 0.4 mol L , which is the highest reported to date for generation of high TPA yields ([70 mol %) in HTW. The presence of two liquid phases during the reaction did not appear to accelerate th...

The process of acute release of tissue-type plasminogen activator (tPA) is important in locally speeding up fibrinolysis. Using a sensitive enzyme-linked immunosorbent assay for tPA, we investigated the acute release of tPA from cultured human umbilical vein endothelial cells. The addition of thrombin (0.003 to 3 NIH U/mL) caused the dose-dependent release of noncomplexed, enzymatically active ...

Current treatment with tissue plasminogen activator (tPA) requires an intravenous infusion (1.5-3 h) because the clearance of tPA from the circulation is rapid (t 1/2 approximately 6 min). We have developed a tPA variant, T103N,N117Q, KHRR(296-299)AAAA (TNK-tPA) that has substantially slower in vivo clearance (1.9 vs. 16.1 ml per min per kg for tPA in rabbits) and near-normal fibrin binding and...

Reperfusion therapy with tissue plasminogen activator (tPA) is a rational therapy for acute ischemic stroke. Properly titrated use of tPA improves clinical outcomes. However, there is also an associated risk of hemorrhagic transformation after tPA therapy. Emerging data now suggest that some of these potentially neurotoxic side effects of tPA may be due to its signaling actions in the neurovasc...